Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
To the Editor: Dr Geba and colleagues1 concluded that rofecoxib (25 mg/d) is more efficacious
than acetaminophen (400 mg/d) and celecoxib (200 mg/d). However, 400 mg/d
of celecoxib would have been a more appropriate comparison dose. In any event,
the differences in outcomes did not appear to be clinically significant.
Merck (which makes rofecoxib) sponsored this study and all authors were
affiliated with either Merck or its speaker's bureau. I fear that the results
of this study may be used to support advertising directly to consumers and
increase the time I will needlessly spend educating my patients.
Henderson P. Rofecoxib vs Celecoxib vs Acetaminophen for Treatment of Osteoarthritis. JAMA. 2002;287(14):1799–1800. doi:10.1001/jama.287.14.1799
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: